The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
新型 CXCR4 拮抗剂 KRH-3955 是一种口服生物利用度高且对人类免疫缺陷病毒 1 型感染具有极强抑制作用的抑制剂：与 AMD3100 的比较研究
期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/AAC.01727-08
Murakami Tsutomu, Kumakura Sei, Yamazaki Toru, Tanaka Reiko, Hamatake Makiko, Okuma Kazu, Huang Wei, Toma Jonathan, Komano Jun, Yanaka Mikiro, Tanaka Yuetsu, Yamamoto Naoki
